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Background: The purpose of this study was to investigate the association between chronic lymphocytic thyroiditis
(CLT) and malignant tumors of the thyroid.
Methods: A retrospective review of 647 patients who underwent thyroid surgery at the Department of Breast and
Thyroid Surgery in Anhui Provincial Hospital, China in 2012 was performed. The clinicopathological characteristics of
patients with thyroid malignancies and CLT were collected. CLT was diagnosed by histopathological method.
Results: Among 647 patients, 144 patients had thyroid malignancies and 108 patients had been diagnosed with
CLT. Moreover, in total, 44 patients had thyroid malignancies coexistent with CLT: forty-one (93.2%) patients had
been diagnosed with the papillary thyroid cancer (PTC); two (4.5%) patients suffered from medullary carcinoma; and
one (2.3%) patient suffered from lymphoma. The morbidity of thyroid malignancies in patients with CLT was significantly
higher than that in patients without CLT (40.7% versus 18.6%; P <0.001). A female preponderance was observed in the
patients with CLT compared with those without CLT (P <0.001). There was no statistically significant difference in the
tumor size (P = 0.073), multifocality (P = 0.0871), neck lymph node metastasis (P = 0.350), age (P = 0.316), microcarcinoma
(P = 0.983) and tumor-node-metastasis (TNM) stage (P = 0.949) between the patients of thyroid malignancies with CLT
and without CLT.
Conclusions: Female predominance was observed in patients with CLT. CLT may have no effect on the progression of
thyroid malignant tumor. Nevertheless, the influences of CLT on the prognosis of the thyroid carcinoma still need to be
investigated with a larger sample size.
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Thyroid cancer is the most common endocrine malig-
nancy and occurs in 8.7 per 100 000 individuals in the
United States, accounting for approximately 1% of all
cancers [1-3]. It has been reported that clinicopathologic
factors, such as sex, age, tumor size, multifocality, extra-
thyroidal extension and lymph node metastasis, are re-
lated to the prognosis of thyroid cancers [4-6]. Different
morphological types of thyroid cancer mainly include
papillary thyroid carcinoma (PTC), follicular carcinoma,
medullary carcinoma, anaplastic carcinoma and thyroid
lymphoma. PTC is the most prevalent manifestation of
thyroid cancer. It represents 70 to 80% of all diagnosed
thyroid cancers [7]. Thyroid lymphoma is a rare thyroid* Correspondence: YiZhangyzh3@163.com
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unless otherwise stated.malignant tumor, accounting for 1 to 5% of all thyroid ma-
lignancies and less than 2% of extranodal lymphomas [8].
Chronic lymphocytic thyroiditis (CLT, or Hashimoto's
thyroiditis (HT)) has been recognized as a common
autoimmune thyroid disorder in which the thyroid gland
is attacked by various antibody and cell-mediated im-
mune processes [9]. The clinical and pathologic associa-
tions between CLT and thyroid epithelial neoplasms
were first described by Dailey et al. in 1955 [10]. Studies
have found that CLT can coexist with other autoimmune
thyroid diseases and thyroid malignancies [11,12]. A
well-established association that patients with CLT have
an increased risk of thyroid lymphoma and PTC has
been proposed [13-16]. In addition, Okayasu et al. [17]
revealed an association between CLT and PTC in the
Japanese, and in white and African American popula-
tions, and also indicated that the possibility of CLT as aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 The general characteristics of patients with
thyroid malignancies and the morbidity of malignancy of








64 (59.3%) 439 (81.4%)
Malignancy (+)
(n = 144)
44 (40.7%) 100 (18.6%)
Age (years) 43.3 ± 13.2 48.3 ± 14.1
Sex (female/male) 41/3 65/35
Papillary carcinoma 41 (93.2%) 93 (93.0%)
Follicular carcinoma 0 2 (2.0%)
Medullary carcinoma 2 (4.5%) 2 (2.0%)
Anaplastic carcinoma 0 3 (3.0%)
Lymphoma 1 (2.3%) 0
CLT, chronic lymphocytic thyroiditis; CLT (+), malignancy of patients with CLT;
CLT (-), malignancy of patients without CLT.
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between PTC and CLT with regard to pathogenesis and
prognostic outcomes of their co-occurrence remains un-
clear among Chinese population; furthermore, the asso-
ciation between the other types of thyroid cancers and
CLT still needs to be studied.
In this present study, we aimed to evaluate the presence
of coexistent CLT in a population of patients who under-
went thyroid surgery at the Department of Breast and Thy-
roid Surgery in Anhui Provincial Hospital, China. Then the
association of CLT with clinicopathological parameters in-
cluding age, sex, tumor size, multifocality, neck lymph
node metastasis, microcarcinoma and TNM stage of pa-
tients with thyroid malignancies was determined.
Methods
Patients
In 2012, 647 patients who had undergone thyroid sur-
gery at the Department of Breast and Thyroid Surgery in
Anhui Provincial Hospital, China were enrolled in this
study. All participants gave written informed consents at
the time of surgery to allow future reviewing of medical
records, and this retrospective study was approved by
the hospital medical ethics committee.
Diagnosis of chronic lymphocytic thyroiditis
The histopathological manifestations of CLT include diffuse
lymphoplasmacytic and plasma cell infiltration, lymphoid
follicle formation with germinal centers, varying degrees of
fibrosis, parenchymal atrophy in the area of normal thyroid
tissue, and the presence of large follicular cells with abun-
dant oxyphilic cells. Only the presence of peri-tumoral
lymphocytic infiltration was not considered as CLT [18-20].
Data collection
The general characteristics of the patients with thyroid
malignancies were recorded, including age, sex and can-
cer types. The clinicopathological parameters, such as
tumor size, multifocality, neck lymph node metastasis,
microcarcinoma and TNM stage, of patients with thyroid
malignancies and with and without CLT were collected to
analyze the effect of coexistent CLT in the patients with thy-
roid cancers.
Meanwhile, the serological examination results, pre-
operative ultrasonographic examination results and sur-
gical methods of patients of thyroid malignancies with
coexistent CLT were collected.
Statistical analysis
Statistical analysis was performed by SPSS 11.5 software
(SPSS, Chicago, IL, USA). The measurement data were
expressed as mean ± standard deviation and analyzed by
t-test. The chi-square (χ2) test was used to analyze theenumeration data. There is significantly statistical differ-
ence when P <0.05.
Results
General characteristics of patients with thyroid
malignancies
The general characteristics of patients with thyroid ma-
lignancies are shown in Table 1. Among the 647 patients
who underwent thyroid surgery, there were 144 patients
(female/male: 106/38; 46.9 ± 13.9 years) with thyroid ma-
lignancies, 108 patients (female/male: 101/7) with CLT
and 395 with other thyroid diseases. Moreover, 44 pa-
tients (female/male: 41/3; 43.3 ± 13.2 years) with thyroid
malignancies had co-existing CLT. Among them, 41 pa-
tients had been diagnosed with papillary carcinoma, 2
patients suffered from medullary carcinoma and 1 pa-
tient developed lymphoma.
Comparison of morbidity of malignancy between patients
with and without chronic lymphocytic thyroiditis
Comparison of morbidity of malignancy between pa-
tients with and without CLT were shown in Table 1.
Thyroid malignancies were detected in 44 (40.7%) of the
108 patients with CLT and 100 (18.6%) of the 539 pa-
tients without CLT. The morbidity of thyroid malignan-
cies between patients with CLT was significantly higher
than patients without CLT (P <0.001).
Clinicopathological parameters of patients with and
without chronic lymphocytic thyroiditis
The differences in clinicopathological parameters be-
tween patients with and without CLT were analyzed in
Table 2. The 144 patients with thyroid malignancies
were mainly at stage I (83/144, 57.6%) and stage II (34/
Table 2 The differences in clinicopathological parameters between patients with and without chronic lymphocytic
thyroiditis (CLT)
Parameters Malignancy (+) CLT (−) Malignancy (+) CLT (+) Total P
(n = 100) (n = 44) (n = 144)
Tumor size (cm)
d ≤2 59 (59.0%) 34 (77.3%) 93 (64.6%) 0.073
2 < d ≤4 28 (28.0%) 8 (18.2%) 36 (25.0%)
d >4 13 (13.0%) 2 (4.5%) 15 (10.4%)
Multifocality
No 79 (79.0%) 36 (81.8%) 115 (79.9%) 0.0871
Yes 21 (21.0%) 8 (22.2%) 29 (20.1%)
Neck lymph node metastasis
No 65 (65.0%) 25 (56.8%) 90 (62.5%) 0.350
Yes 35 (35.0%) 19 (43.2%) 54 (37.5%)
Gender
Female 65 (65.0%) 41 (93.2%) 106 (73.6%) <0.001
Male 35 (35.0%) 3 (6.8%) 38 (26.4%)
Age
<45 years 41 (41.0%) 22 (50.0%) 63 (43.7%) 0.316
≥45 years 59 (59.0%) 22 (50.0%) 81 (56.3%)
Microcarcinoma
No 68 (68.0%) 30 (68.2%) 98 (68.1%) 0.983
Yes 32 (32.0%) 14 (31.8%) 46 (31.9%)
TNM stage
I 57 (68.7%) 26 (31.3%) 83 (57.6%) 0.949
II 23 (67.6%) 11 (32.4%) 34 (23.6%)
III 11 (73.3%) 4 (26.7%) 15 (10.4%)
IVA 9 (75.0%) 3 (25.0%) 12 (8.3%)
CLT, chronic lymphocytic thyroiditis; CLT (+), malignancy of patients with CLT; CLT (−), malignancy of patients without CLT; TNM stage,
tumor-node-metastasis stage.
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in the tumor size (P = 0.073), multifocality (P = 0.0871),
neck lymph node metastasis (P = 0.350), age (P = 0.316),
microcarcinoma (P = 0.983) and TNM stage (P = 0.949) be-
tween the patients of thyroid malignancies with CLT
and without CLT. Female predominance was observed
in patients with CLT compared to those without CLT
(P < 0.001).
Diagnosis results and surgical methods for patients of
thyroid malignancies with coexistent chronic lymphocytic
thyroiditis
There were 44 patients of thyroid malignancies with co-
existent CLT, among which 37 patients had received
serological examination. The level of serum thyroperoxi-
dase antibody was elevated in 23 (62.2%) patients, along
with the level of thyroglobulin antibodies in 32 (86.5%)
patients. Preoperative ultrasonographic examination wasapplied to the 44 patients who had thyroid malignancies
with coexistent CLT: nodular hyperplasia was detected
in all patients and accounted for up to 100%, a solitary
nodule was found in 15 (34.1%) patients, multiple nod-
ules were present in 19 (65.9%) patients, spot calcifica-
tion was found in 25 (56.8%) patients, irregular and
unclear border appeared in 18 (40.9%) patients, and cer-
vical lymph node enlargement were identified in 23
(52.3%) patients. Seven different surgical methods were
assigned to these 44 patients who had thyroid malignan-
cies and co-existing CLT. In total, 13 (29.5%) patients re-
ceived a unilateral lobectomy plus central region lymph
node dissection, and 10 (22.7%) patients received a uni-
lateral lobectomy plus contralateral subtotal lobectomy
with central region lymph node dissection. Moreover, a
bilateral thyroidectomy plus central region lymph node
dissection was assigned to six (13.6%) patients. In addition,
12 (27.3%) patients were equally allotted to 3 groups using
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dissection, bilateral thyroidectomy plus unilateral neck dis-
section and bilateral thyroidectomy plus bilateral neck dis-
section. The other three (6.8%) patients received unilateral
lobectomy plus unilateral neck dissection. All patients re-
ceived endocrine therapy by means of oral drugs such as
levothyroxine sodium, as well as the clinical follow-up after
operation. The follow-up period was from 10 months to
22 months (average 15 months). There was no death or
case recurrence.
Discussion
The association between CLT and thyroid lymphoma and
PTC has been well-established in Japan and America;
however, the correlation between CLT and PTC in our
country, as well as the influence of CLT on other thyroid
malignancies, still needs to be studied. In our study, the
association of CLT with clinicopathological parameters of
patients with thyroid malignancies was evaluated. The re-
sults showed that the morbidity of thyroid malignancies in
patients with CLT was significantly higher than that in pa-
tients without CLT. A female preponderance was observed
in the patients with CLT compared with those without
CLT. There was no statistically significant difference in the
tumor size, multifocality, neck lymph node metastasis, age,
microcarcinoma or TNM stage between the patients of
thyroid malignancies with CLT and without CLT.
Among the 44 patients who had thyroid malignancies
coexistent with CLT, 41 had been diagnosed with papil-
lary carcinoma, 2 suffered from medullary carcinoma
and 1 suffered from lymphoma. The results revealed that
coexistence of CLT mainly occurred in the patients with
PTC [21,22], a result in accordance with other studies.
In addition, we found that the rate of thyroid malignan-
cies in patients with CLT (40.7%) is significantly higher
than that in patients without CLT (18.6%). The presence
of CLT has been reported to be in 0.5 to 38% of patients
with PTC [17,18,23]. The presence of thyroid malignan-
cies in patients with CLT in our study is slightly higher
than that reported in the literature. The reasons may be
multifactorial. First, the indications for surgery in our
department are stricter, and the surgery was performed
on patients with thyroid nodules that were highly sus-
pected for thyroid cancer. Second, racial difference,
genetic factors, and dietary factors might contribute to
the result. Third, it should be note that the sample size
of our study was relatively small compared with other
studies, consisting of only 647 people. Some studies
have reported that the prevalence of CLT is significantly
increased in patients with PTC [24,25]. Therefore, patients
with thyroid nodules and who are suspected of having CLT
need to be carefully monitored since the possibility of ma-
lignancy is raised. Once thyroid cancer is diagnosed, themost cost-effective approach should be chosen. Several
treatment methods for patients with thyroid cancer, such
as surgical resection, radioactive iodine ablation, and TSH
suppression therapy, are all in favor [26]. However, contro-
versy still exists in many areas. Accordingly, thyroidectomy
is recommended for differentiated cancer (for example,
papillary and follicular cancer) [7]. In contrast, for undif-
ferentiated thyroid cancer (for example, anaplastic cancer)
that is associated with aggression and invasion, chemo-
therapy and radiation treatment might provide more
benefit to these patients compared to surgery [27]. In our
study, among the 44 patients who had thyroid malignan-
cies and co-existing CLT, papillary carcinoma was the
main type of thyroid malignancy. Therefore, seven differ-
ent surgical methods were assigned to these 44 patients.
In addition, endocrine therapy, such as oral drugs, was
provided to all patients after operation. Adjuvant therapy
was also assigned to patients with extracapsular extensions
or more lymph node metastasis. In our subsequent follow-
up after operation, we found that there was no case of
death or recurrence, possibly due to a good prognosis for
thyroid malignancies and the short term of the follow-up.
In our study, a female predominance was observed in
patients with CLT compared to those without CLT. Many
previous studies have found that patients with CLT are
predominately female in comparison with patients without
CLT [28,29]. This result is consistent with previous stud-
ies. However, no statistically significant difference was
found in the tumor size, multifocality, neck lymph node
metastasis, age, microcarcinoma and TNM stage between
patients with thyroid malignancies and CLT and those pa-
tients with thyroid malignancies and no CLT. Generally
speaking, immune infiltration in human tumors as a prog-
nostic factor could not be ignored [30,31]. CLT is charac-
terized by progressive loss of thyroid epithelial cells and
replacement of inflammatory cell infiltrate that produces
chemokines, growth factors and cytokines [32-34]. Some
studies have reported that the lymphocytic infiltration in
PTC is associated with a lower recurrence rate, a better
prognosis, and less aggressive disease [19,35,36]. However,
Kebebew et al. have reported that thyroid lymphocytic in-
filtration is not an independent prognostic factor and
could not reduce the recurrence rate or frequency of dis-
tant metastasis [23]. Among the 37 patients who received
serological examination, we found that the level of serum
thyroperoxidase antibody was high in 23 (62.2%) patients,
as well as the level of thyroglobulin antibodies in 32 (86.5%)
patients. Because thyroglobulin and thyroperoxidase are the
two primary antigens in autoimmune thyroiditis, patients
who suffered from CLT would make corresponding auto-
antibodies against thyroid-specific antigens [32,37,38]. It
has been reported that serum thyroglobulin antibody was
an independent predictor for thyroid malignancy in thyroid
nodules [34,39].
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In conclusion, we analyzed the association of CLT with
clinicopathological parameters of patients with thyroid
malignancies. The results of our study indicate that the
CLT may have no effect on the progression of thyroid
malignant tumor. Nevertheless, the influences of CLT on
the prognosis of the thyroid carcinoma still need to be
investigated based on a larger sample size.
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